论文部分内容阅读
最近全身应用大剂量重组白介素-2(rIL-2)治疗癌症取得一些效果,但总的结果并不尽如人意,因此普遍认为此非上策。过去,IL-2常作为化疗药物,以最大耐受剂量使用,这样不仅会导致许多毒副作用,而且它主要是通过低亲和力受体激活非特异性的淋巴因子激活的杀伤细胞(LAK)的活性,并不能提高机体的免疫力。另外几组资料表明,瘤体内小剂量应用IL-2相当有效,而且无毒副作用,小鼠体内占体重6％的肿瘤,可通过局部应用小剂量IL-2而消除。不仅如此,局部应用还可使远处肿瘤消失。这种疗法对鼠的不同类型肿瘤,豚鼠肝细胞癌,牛的外阴乳头状
The recent systemic application of large doses of recombinant interleukin-2 (rIL-2) in the treatment of cancer has yielded some results, but the overall results are not satisfactory, and it is generally believed that this is not the best strategy. In the past, IL-2 was often used as a chemotherapeutic agent at the maximum tolerated dose, which not only resulted in many toxic side effects, but also its activation of nonspecific lymphokine-activated killer cells (LAKs) mainly through low-affinity receptors. Does not improve the body’s immune system. Several other data suggest that the use of IL-2 in tumors at low doses is quite effective and has no toxic or side effects. Tumors with a body weight of 6% in mice can be eliminated by local application of low-dose IL-2. Not only that, local application can also make distant tumors disappear. This therapy treats different types of tumours in mice, guinea pig hepatocellular carcinoma, bovine genital papillae